Xcout IntelHCW Biologics Inc.
HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for patients with a variety of cancers, such as pancreatic, ovarian, breast, prostate, and colorectal, as well as for pulmonary fibrosis. Another key product, HCW9302, targets autoimmune conditions like alopecia areata and various metabolic disorders. Beyond these, HCW Biologics is also developing HCW9201, a cell-based therapy currently in Phase II clinical trials for the treatment of relapsed/refractory acute myeloid leukemia. Additionally, HCW9206 is under development specifically for acute myeloid leukemia. Incorporated in 2018, the company's corporate headquarters are situated in Miramar, Florida.
Subscribe to see HCW Biologics Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
HCW Biologics Inc. at a glance
HCW Biologics Inc. is a biotech company headquartered in Miramar, United States. It is publicly listed (HCWB) with a market capitalisation of $556,226. Xcout tracks 23 named people at HCW Biologics Inc., including Rebecca Byam (Chief Financial Officer).
HCW Biologics Inc. leadership
- Rebecca ByamChief Financial Officer
- Peter RhodeChief Scientific Officer & Vice President of Clinical Operations
- Hing C. WongFounder, Chief Executive Officer, Director & Secretary
- Lee D. FlowersSenior Vice President of Business Development
- Lee FlowersSenior Vice President Business Development
- Jack Egan, PhDVice President of Manufacturing and Development
17 more named people on record for HCW Biologics Inc., with roles, board committees and tenure — see the full roster →
HCW Biologics Inc. competitors
A few of HCW Biologics Inc.'s closest competitors — see the full list of competitors and alternatives →
Impact BioMedical Inc. is a pioneering biotechnology company incorporated in 2018 and based in Houston, Texas, dedicated to discovering, developing, and patenting innovative healthcare products, drug pipelines, and technology platforms.
Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Avammune Therapeutics is an R&D-driven drug discovery company headquartered in Philadelphia, Pennsylvania. The company focuses on developing novel, modality-agnostic immunotherapies and cancer therapies to address high unmet medical needs in hard-to-treat solid tumors.
IpiNovyx Bio, Inc. is a biopharmaceutical company that discovers and develops targeted proteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases. Utilizing a proprietary technology platform, the company focuses on advancing selective and reversible immunoproteasome inhibitors to create safer and more effective therapies for patients.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Amphivena Therapeutics, Inc. is a privately held, clinical-stage biotechnology company based in South San Francisco, California. The company specializes in immuno-oncology, developing a platform of dual-function biologics and selective T cell engagers for the treatment of hematological conditions.
Get HCW Biologics Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on HCW Biologics Inc. in Xcout Intel
- 23 named people with titles, LinkedIn and board committees
- 6 corporate events with sources — deals, leadership changes, layoffs
- The full competitor set, tracking, exports and API access